Table 1.
Baseline characteristics of 282 pancreatic ductal adenocarcinoma patients undergoing radical R0 resection, n (%)
| Characteristic | Patients (n = 282) |
TNM stage
|
|||||
|
IA (n = 20, 7.1%)
|
IB (n = 92, 32.6%)
|
IIA (n = 49, 17.4%)
|
IIB (n = 92, 32.6%)
|
III (n = 29, 10.3%)
|
P
value
|
||
| Age (yr) | 61 (31-81) | 63.5 (50-73) | 62 (31-81) | 63 (38-78) | 59 (31-74) | 59 (42-70) | 0.076 |
| > 60 | 136 (48.2) | 12 (60.0) | 52 (56.5) | 31 (63.3) | 39 (42.4) | 12 (41.4) | |
| ≤ 60 | 146 (51.8) | 8 (40.0) | 40 (43.5) | 18 (36.7) | 53 (57.6) | 17 (58.6) | |
| Sex | 0.421 | ||||||
| Male | 151 (53.5) | 7 (35.0) | 50 (54.3) | 25 (51.0) | 51 (55.4) | 18 (62.1) | |
| Female | 131 (46.5) | 13 (65.0) | 42 (45.7) | 24 (49.0) | 41 (44.6) | 11 (37.9) | |
| Blood type | 0.475 | ||||||
| A | 87 (30.9) | 5 (25.0) | 26 (28.3) | 13 (26.5) | 30 (32.6) | 13 (44.8) | |
| B | 93 (33.0) | 7 (35.0) | 34 (37.0) | 14 (28.6) | 27 (29.3) | 11 (37.9) | |
| AB | 22 (7.8) | 1 (5.0) | 6 (6.5) | 4 (8.2) | 11 (12.0) | 0 | |
| O | 80 (28.4) | 7 (35.0) | 26 (28.3) | 18 (36.7) | 24 (26.1) | 5 (17.2) | |
| Diabetes | 0.816 | ||||||
| Absent | 201 (71.3) | 15 (75.0) | 66 (71.7) | 33 (67.3) | 64 (69.6) | 23 (79.3) | |
| Present | 81 (28.7) | 5 (25.0) | 26 (28.3) | 16 (32.7) | 28 (30.4) | 6 (20.7) | |
| Smoking status | 0.604 | ||||||
| Absent | 215 (76.2) | 13 (65.0) | 74 (80.4) | 37 (75.5) | 68 (73.9) | 23 (79.3) | |
| Present | 67 (23.8) | 7 (35.0) | 18 (19.6) | 12 (24.5) | 24 (26.1) | 6 (20.7) | |
| Alcohol consumption | 0.296 | ||||||
| Absent | 235 (83.3) | 14 (70.0) | 78 (84.8) | 41 (83.7) | 75 (81.5) | 27 (93.1) | |
| Present | 47 (16.7) | 6 (30.0) | 14 (15.2) | 8 (16.3) | 17 (18.5) | 2 (6.9) | |
| Family history of cancer | 0.604 | ||||||
| Absent | 271 (96.1) | 20 (100.0) | 88 (95.7) | 46 (93.9) | 88 (95.7) | 29 (100.0) | |
| Present | 11 (3.9) | 0 | 4 (4.3) | 3 (6.1) | 4 (4.3) | 0 | |
| Clinical symptoms | 0.021 | ||||||
| Absent | 57 (20.2) | 8 (40.0) | 24 (26.1) | 7 (14.3) | 16 (17.4) | 2 (6.9) | |
| Present | 225 (79.8) | 12 (60.0) | 68 (73.9) | 42 (85.7) | 76 (82.6) | 27 (93.1) | |
| Open surgery approach | < 0.001 | ||||||
| Pancreaticoduodenectomy | 130 (46.1) | 11 (55.0) | 48 (52.2) | 10 (20.4) | 40 (43.5) | 21 (72.4) | |
| Distal pancreatectomy with splenectomy | 152 (53.9) | 9 (45.0) | 44 (47.8) | 39 (79.6) | 52 (56.5) | 8 (27.6) | |
| Tumor location | < 0.001 | ||||||
| Head and neck | 130 (46.1) | 11 (55.0) | 48 (52.2) | 10 (20.4) | 40 (43.5) | 21 (72.4) | |
| Body and tail | 152 (53.9) | 9 (45.0) | 44 (47.8) | 39 (79.6) | 52 (56.5) | 8 (27.6) | |
| Degree of differentiation | 0.410 | ||||||
| Well | 34 (12.1) | 0 | 11 (12.0) | 6 (12.2) | 13 (14.1) | 4 (13.8) | |
| Moderately | 217 (77.0) | 16 (80.0) | 67 (72.8) | 38 (77.6) | 73 (79.3) | 23 (79.3) | |
| Poorly | 31 (11.0) | 4 (20.0) | 14 (15.2) | 5 (10.2) | 6 (6.5) | 2 (6.9) | |
| Lymphovascular invasion | < 0.001 | ||||||
| Absent | 203 (72.0) | 17 (85.0) | 73 (79.3) | 40 (81.6) | 62 (67.4) | 11 (37.9) | |
| Present | 79 (28.0) | 3 (15.0) | 19 (20.7) | 9 (18.4) | 30 (32.6) | 18 (62.1) | |
| Perineural invasion | 0.091 | ||||||
| Absent | 70 (24.8) | 5 (25.0) | 25 (27.2) | 17 (34.7) | 21 (22.8) | 2 (6.9) | |
| Present | 212 (75.2) | 15 (75.0) | 67 (72.8) | 32 (65.3) | 71 (77.2) | 27 (93.1) | |
| Capsular invasion | 0.182 | ||||||
| Absent | 49 (17.4) | 4 (20.0) | 18 (19.6) | 13 (26.5) | 10 (10.9) | 4 (13.8) | |
| Present | 233 (82.6) | 16 (80.0) | 74 (80.4) | 36 (73.5) | 82 (89.1) | 25 (86.2) | |
| Maximal tumor diameter (cm) | < 0.001 | ||||||
| > 4 | 88 (31.2) | 0 | 1 (1.1) | 48 (98.0) | 33 (35.9) | 6 (20.7) | |
| ≤ 4 | 194 (68.8) | 20 (100.0) | 91 (98.9) | 1 (2.0) | 59 (64.1) | 23 (79.3) | |
| T stage | < 0.001 | ||||||
| T1 | 34 (12.1) | 20 (100.0) | 0 | 0 | 12 (13.0) | 2 (6.9) | |
| T2 | 159 (56.4) | 0 | 91 (98.9) | 0 | 47 (51.1) | 21 (72.4) | |
| T3 | 89 (31.6) | 0 | 1 (1.1) | 49 (100.0) | 33 (35.9) | 6 (20.7) | |
| Lymph node metastasis | < 0.001 | ||||||
| Absent | 161 (57.1) | 20 (100.0) | 92 (100.0) | 49 (100.0) | 0 | 0 | |
| Present | 121 (42.9) | 0 | 0 | 0 | 92 (100.0) | 29 (100.0) | |
| N stage | < 0.001 | ||||||
| N0 | 161 (57.1) | 20 (100.0) | 92 (100.0) | 49 (100.0) | 0 | 0 | |
| N1 | 92 (32.6) | 0 | 0 | 0 | 92 (100.0) | 0 | |
| N2 | 29 (10.3) | 0 | 0 | 0 | 0 | 29 (100.0) | |
| Preoperative CA19-9 level (U/mL) | 172.4 (0.6-55412.0) | 125.6 (3.4-908.8) | 157.0 (0.6-16827.0) | 172.4 (1.4-4510.0) | 189.5 (12.9-55412.0) | 186.2 (29.8-4839.0) | 0.158 |
| > 336.4 | 77 (27.3) | 2 (10.0) | 21 (22.8) | 13 (26.5) | 31 (33.7) | 10 (34.5) | |
| ≤ 336.4 | 205 (72.7) | 18 (90.0) | 71 (77.2) | 36 (73.5) | 61 (66.3) | 19 (65.5) | |
| Preoperative fibrinogen concentration (g/L) | 3.02 (1.20-6.70) | 3.21 (1.20-5.00) | 3.27 (1.98-6.70) | 3.40 (1.83-5.92) | 3.13 (2.06-5.53) | 3.67 (1.49-5.94) | 0.099 |
| > 3.31 | 141 (50.0) | 8 (40.0) | 44 (47.8) | 30 (61.2) | 40 (43.5) | 19 (65.5) | |
| ≤ 3.31 | 141 (50.0) | 12 (60.0) | 48 (52.2) | 19 (38.8) | 52 (56.5) | 10 (34.5) | |
| Preoperative D-Dimer concentration (g/L) | 0.52 (0.12-582.00) | 0.48 (0.16-145.00) | 0.52 (0.12-430.00) | 0.53 (0.12-582.00) | 0.52 (0.16-159.00) | 0.54 (0.15-157.00) | 0.608 |
| > 0.53 | 117 (41.5) | 8 (40.0) | 37 (40.2) | 23 (46.9) | 34 (37.0) | 15 (51.7) | |
| ≤ 0.53 | 165 (58.5) | 12 (60.0) | 55 (59.8) | 26 (53.1) | 58 (63.0) | 14 (48.3) | |
| Adjuvant therapy | 0.621 | ||||||
| Absent | 124 (44.0) | 6 (30.0) | 42 (45.7) | 24 (49.0) | 41 (44.6) | 11 (37.9) | |
| Present | 158 (56.0) | 14 (70.0) | 50 (54.3) | 25 (51.0) | 51 (55.4) | 18 (62.1) | |
TNM: Tumor, node and metastasis.